SecProbe.io

CORRESP
1
filename1.htm

Biodexa Pharmaceuticals PLC

1 Caspian Point

Caspian Way

Cardiff, CF10 4DQ

United Kingdom

January 23, 2025

VIA EDGAR

Securities and Exchange Commission

Division of Corporate Finance

100 F Street, N.E.

Washington, DC 20549

Attention: Christopher Edwards

  Re: Biodexa Pharmaceuticals PLC

Registration Statement on Form F-1 (File No. 333-284350)

Request for Acceleration of Effective Date

Ladies and Gentlemen:

Pursuant to Rule 461 of the
General Rules and Regulations under the Securities Act of 1933, as amended, Biodexa Pharmaceuticals PLC (the “Registrant”)
hereby respectfully requests that the Securities and Exchange Commission accelerate the effective date of the above-referenced Registration
Statement on Form F-1 (the “Registration Statement”) and declare the Registration Statement effective as of 4:30 p.m., Eastern
Time, on January 27, 2025, or as soon as practicable thereafter.

The Registrant requests that
it be notified of such effectiveness by a telephone call to Jason S. McCaffrey of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.,
counsel to the Registrant, at (617) 348-4416 or by an email to JSMcCaffrey@mintz.com.

Thank you for your assistance.
If you should have any questions, please contact Mr. McCaffrey at (617) 348-4416.

    Very truly yours,

    BIODEXA PHARMACEUTICALS PLC

    By:
    /s/
     Stephen Stamp

    Name:

     Stephen Stamp

    Title:

     Chief Executive Officer & Chief Financial Officer

 cc: Jason S. McCaffrey, Esq., Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.